Basilea

FDA Approves Basilea’s ZEVTERA® for Severe Bacterial Infections, Including Pediatric Use

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for…

1 month ago

Basilea’s Antifungal Cresemba Sales in Latin America Trigger Milestone Payment from Partner Knight Therapeutics

(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN) has announced that its partner Knight Therapeutics Inc. (TSX: GUD) exceeded the sales…

4 months ago

Basilea’s Antifungal Drug Cresemba Surpasses Sales Threshold in Asia Pacific, Triggering $1.25 Million Milestone Payment

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company dedicated to addressing severe bacterial and fungal infections, has announced that its…

6 months ago

Basilea to receive sales milestone payments from Astellas based on exceeding certain thresholds from the sales of antifungal Cresemba®

BASEL, 11-Dec-2018 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the sales of the antifungal Cresemba® (isavuconazole) by Astellas…

5 years ago

Shenzhen China Resources Gosun Pharmaceutical Co. granted exclusive license to develop, manufacture and to commercialize Basilea’s antibiotic Zevtera® (ceftobiprole) in China, Hong Kong and Macau

BASEL, 02-Oct-2017 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into…

7 years ago